Renaissance Technologies's HBIO Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 102,124 shares of Harvard Bioscience, Inc. (HBIO) worth $683,006, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in HBIO, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2020, adding 35,530 shares. Largest reduction occurred in Q3 2019, reducing 38,579 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Harvard Bioscience (HBIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Harvard Bioscience (HBIO) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +15,276 | Add 17.59% | 102,124 | $6.69 |
| Q3 2025 | +7,650 | Add 9.66% | 86,848 | $4.38 |
| Q2 2025 | -9,172 | Reduce 10.38% | 79,198 | $4.44 |
| Q1 2025 | +17,392 | Add 24.50% | 88,370 | $5.66 |
| Q4 2024 | -1,430 | Reduce 1.97% | 70,978 | $21.10 |
| Q3 2024 | -2,120 | Reduce 2.84% | 72,408 | $26.90 |
| Q2 2024 | +4,280 | Add 6.09% | 74,528 | $28.50 |
| Q1 2024 | -1,790 | Reduce 2.48% | 70,248 | $42.41 |
| Q4 2023 | -2,430 | Reduce 3.26% | 72,038 | $53.50 |
| Q3 2023 | -753 | Reduce 1.00% | 74,468 | $43.00 |
| Q2 2023 | +2,220 | Add 3.04% | 75,221 | $0.05 |
| Q1 2023 | -430 | Reduce 0.59% | 73,001 | $0.04 |
| Q4 2022 | -11,716 | Reduce 13.76% | 73,431 | $0.03 |
| Q3 2022 | -14,979 | Reduce 14.96% | 85,147 | $25.60 |
| Q2 2022 | +5,282 | Add 5.57% | 100,126 | $36.00 |
| Q1 2022 | +4,250 | Add 4.69% | 94,844 | $62.10 |
| Q4 2021 | -17,050 | Reduce 15.84% | 90,594 | $70.50 |
| Q3 2021 | -15,690 | Reduce 12.72% | 107,644 | $69.80 |
| Q2 2021 | -19,430 | Reduce 13.61% | 123,334 | $83.30 |
| Q1 2021 | +21,120 | Add 17.36% | 142,764 | $54.60 |
| Q4 2020 | -3,491 | Reduce 2.79% | 121,644 | $42.90 |
| Q3 2020 | +21,922 | Add 21.24% | 125,135 | $30.10 |
| Q2 2020 | +35,530 | Add 52.49% | 103,213 | $31.00 |
| Q1 2020 | +14,083 | Add 26.27% | 67,683 | $22.10 |
| Q4 2019 | +2,079 | Add 4.04% | 53,600 | $30.50 |
| Q3 2019 | -38,579 | Reduce 42.82% | 51,521 | $30.74 |
| Q2 2019 | +27,950 | Add 44.97% | 90,100 | $20.00 |
| Q1 2019 | -7,841 | Reduce 11.20% | 62,150 | $43.11 |
| Q4 2018 | -17,979 | Reduce 20.44% | 69,991 | $31.80 |
| Q3 2018 | +13,223 | Add 17.69% | 87,970 | $52.50 |
| Q2 2018 | -983 | Reduce 1.30% | 74,747 | $53.50 |
| Q1 2018 | +14,517 | Add 23.72% | 75,730 | $49.99 |
| Q4 2017 | +709 | Add 1.17% | 61,213 | $33.00 |
| Q3 2017 | +1,504 | Add 2.55% | 60,504 | $37.50 |
| Q2 2017 | +2,950 | Add 5.26% | 59,000 | $25.49 |
| Q1 2017 | +3,130 | Add 5.91% | 56,050 | $25.99 |
| Q4 2016 | +2,050 | Add 4.03% | 52,920 | $30.50 |
| Q3 2016 | -2,550 | Reduce 4.77% | 50,870 | $27.21 |
| Q2 2016 | -2,330 | Reduce 4.18% | 53,420 | $28.60 |
| Q1 2016 | -930 | Reduce 1.64% | 55,750 | $30.21 |
| Q4 2015 | -3,430 | Reduce 5.71% | 56,680 | $34.70 |
| Q3 2015 | -2,390 | Reduce 3.82% | 60,110 | $37.80 |
| Q2 2015 | +1,580 | Add 2.59% | 62,500 | $57.01 |
| Q1 2015 | +948 | Add 1.58% | 60,920 | $58.21 |
| Q4 2014 | -3,238 | Reduce 5.12% | 59,972 | $56.69 |
| Q3 2014 | -10,830 | Reduce 14.63% | 63,210 | $40.90 |
| Q2 2014 | +15,583 | Add 26.66% | 74,040 | $45.50 |
| Q1 2014 | +9,537 | Add 19.50% | 58,457 | $47.40 |
| Q4 2013 | +6,903 | Add 16.43% | 48,920 | $47.00 |
| Q3 2013 | +5,117 | Add 13.87% | 42,017 | $52.60 |
| Q2 2013 | +36,900 | Add 0.00% | 36,900 | $46.99 |
Renaissance Technologies's Harvard Bioscience Investment FAQs
Renaissance Technologies first purchased Harvard Bioscience, Inc. (HBIO) in Q2 2013, acquiring 36,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Harvard Bioscience, Inc. (HBIO) for 51 quarters since Q2 2013.
Renaissance Technologies's largest addition to Harvard Bioscience, Inc. (HBIO) was in Q2 2013, adding 36,900 shares worth $1.73 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 102,124 shares of Harvard Bioscience, Inc. (HBIO), valued at approximately $683,006.
As of the Q4 2025 filing, Harvard Bioscience, Inc. (HBIO) represents approximately 0.00% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Harvard Bioscience, Inc. (HBIO) was 142,764 shares, as reported at the end of Q1 2021.